No abstract

The NS3/4 protease inhibitors boceprevir and telaprevir in conjunction with peginterferon α and ribavirin (triple therapy) increase the rate of a sustained virological response in patients with genotype-1 chronic hepatitis C but, to achieve a successful result, good compliance is vital. As part of a pharmaceutical care programme, in the Outpatient Pharmacy we developed information leaflets to help patients understand the objectives of triple therapy, to be aware and prevent the possible side effects and to teach patients how to take the medicines.

[72.0, 216.0] euros, p = 0.136) and CERA (196.7 [172.1, 295. CERA (393.4 [98.3, 491.7] euros vs. 147.5 [98.3, 196.7] euros, p = 0.035). Conclusions The cost of epoetin and CERA is greater for both patients with a kidney transplant and patients on dialysis. However there was no difference regarding darbepoetin α.No conflict of interest.